Shares of Endologix, Inc. (NASDAQ:ELGX) have been assigned a consensus recommendation of “Hold” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $22.75.
Several research analysts recently weighed in on the company. Zacks Investment Research lowered Endologix from a “hold” rating to a “sell” rating in a research report on Monday, March 11th. BTIG Research reiterated a “buy” rating on shares of Endologix in a research report on Tuesday, February 26th. Stifel Nicolaus set a $7.00 price objective on Endologix and gave the stock a “hold” rating in a research report on Monday, April 1st. Finally, ValuEngine upgraded Endologix from a “hold” rating to a “buy” rating in a research report on Wednesday, March 6th.
NASDAQ:ELGX opened at $6.05 on Friday. Endologix has a one year low of $5.20 and a one year high of $67.20. The company has a quick ratio of 1.25, a current ratio of 2.03 and a debt-to-equity ratio of 5.00. The company has a market capitalization of $62.92 million, a P/E ratio of -0.84 and a beta of 0.58.
In other Endologix news, CEO John Onopchenko acquired 30,257 shares of the stock in a transaction on Wednesday, April 3rd. The shares were bought at an average price of $6.61 per share, with a total value of $199,998.77. Following the acquisition, the chief executive officer now owns 96,360 shares of the company’s stock, valued at $636,939.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Vaseem Mahboob purchased 15,128 shares of the firm’s stock in a transaction dated Wednesday, April 3rd. The shares were purchased at an average cost of $6.61 per share, for a total transaction of $99,996.08. Following the purchase, the chief financial officer now directly owns 76,820 shares in the company, valued at $507,780.20. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 48,410 shares of company stock worth $319,990. 1.40% of the stock is owned by insiders.
Large investors have recently made changes to their positions in the company. Deutsche Bank AG raised its position in shares of Endologix by 121.3% during the 4th quarter. Deutsche Bank AG now owns 433,335 shares of the medical instruments supplier’s stock worth $309,000 after purchasing an additional 237,555 shares during the last quarter. Geode Capital Management LLC raised its holdings in Endologix by 22.9% in the 4th quarter. Geode Capital Management LLC now owns 1,059,281 shares of the medical instruments supplier’s stock valued at $757,000 after acquiring an additional 197,351 shares during the last quarter. Norges Bank acquired a new position in Endologix in the 4th quarter valued at $545,000. Macquarie Group Ltd. acquired a new position in Endologix in the 4th quarter valued at $46,000. Finally, Jane Street Group LLC raised its holdings in Endologix by 54.6% in the 4th quarter. Jane Street Group LLC now owns 93,572 shares of the medical instruments supplier’s stock valued at $67,000 after acquiring an additional 33,044 shares during the last quarter.
Endologix Company Profile
Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.
Recommended Story: How can you know how many shares are floating?
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.